KB 107
Alternative Names: KB-107Latest Information Update: 28 Apr 2023
At a glance
- Originator Krystal Biotech
- Class Gene therapies; Skin disorder therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epidermolysis bullosa
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Epidermolysis-bullosa in USA (Parenteral)
- 27 Sep 2019 Krystal Biotech has patent protection for the Skin TARgeted Delivery (STAR-D) platform and its uses in USA
- 08 Apr 2019 Krystal Biotech has patent protection for skin targeted delivery platform in USA (Krystal Biotech website, April 2019)